Immutep (NasdaqGM:IMMP) 2025 Conference November 19, 2025 05:00 PM ET Speaker1Very good. We're going to have a bit of a fireside discussion today, which I'm very much looking forward to. Before I get to some questions, I'll just provide a brief introduction for our audience. Immutep is a clinical stage company with its lead drug candidate in phase three clinical trials for lung cancer, as well as having a second asset undergoing trials for an autoimmune condition. Under Mark's leadership, Immutep has reache ...